VivoSeq
Respiratory

Pulmonary Fibrosis

33

Pipeline Programs↗

10

Active Trials↗

19

Companies Involved↗

Pulmonary Fibrosis is a moderately active landscape with 33 programs across 19 companies. The most active players are Indalo Therapeutics, Inc., Horizon Therapeutics Ireland DAC, Guangdong Hengrui Pharmaceutical Co., Ltd. 6 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

15/100

Mech. Concentration

8/100

Completion Rate

79/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Indalo Therapeutics, Inc.

1 program

Phase 1H

Horizon Therapeutics Ireland DAC

1 program

Phase 1Guangdong Hengrui Pharmaceutical Co., Ltd logo

Guangdong Hengrui Pharmaceutical Co., Ltd

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2A

Avalyn Pharma Inc.

1 program

Phase 2I

Immunex

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical2

Nintedanib

Boehringer Ingelheim

Corticosteroids Alone

Mansoura University

Phase 14

Interferon Gamma-1b

Horizon Therapeutics Ireland DAC

CC-90001

Bristol-Myers Squibb

Epigallocatechin-3-Gallate

University of Rochester

Cell Free Fat Extract(ceffe)

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Phase 215

Etanercept

Immunex

Pirfenidone

Legacy Health System

Bevacizumab

Bio-Thera Solutions

Dexamethasone

Aspen Global Incorporated

Bortezomib

Shilpa Grover, MD, MPH

Phase 36

Morphine Sulfate

Merck & Co.

Bosentan

Johnson & Johnson

Nerandomilast

Boehringer Ingelheim

Morphine Hydrochloride

Luye Pharma Group Ltd.

BMS-986278

Bristol-Myers Squibb

Approved6

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Cyclophosphamide

Baxter Healthcare Corporation

Treprostinil

United Therapeutics

Pomalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Colchicine

Alnylam Pharmaceuticals

Analysis

Modality Breakdown

88%

Small molecule

36 of 41 classified programs — the dominant modality here.

12%ALL OTHERSProtein / enzyme25%Cell therapy25%Monoclonal antibody12%

Small molecule leads; the ring shows all 41 classified programs, each share of the total. Modality classified for 98% of 44 pipeline programs.

Analysis

Trial Status

41

clinical trials

Completed15 · 37%
Unknown status12 · 29%
Recruiting5 · 12%
Active, not recruiting4 · 10%
Terminated3 · 7%
Suspended1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

41 trials

Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis
Recruiting·Guangdong Hengrui Pharmaceutical Co., Ltd logoGuangdong Hengrui Pharmaceutical Co., Ltd·Phase 2·NCT07192939·270 enrolled
Advanced Imaging for Pulmonary Fibrosis
Recruiting·—·Phase 2·NCT06532071·60 enrolled
Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
Recruiting·PPeking Union Medical College Hospital·Phase 1·NCT05121779·80 enrolled
Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04541680·250 enrolled
A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT07201922·80 enrolled
Clinical Study of Allogeneic Fat Decellularized Active Protein in the Treatment of Pulmonary Fibrosis
Active, not recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 1·NCT05883293·7 enrolled
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Active, not recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT06025578·1,057 enrolled
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Participants With PPF
Active, not recruiting·AAvalyn Pharma Inc.·Phase 2·NCT06329401·375 enrolled
Analysis of Specimens From Individuals With Pulmonary Fibrosis
Active, not recruiting·NNational Human Genome Research Institute (NHGRI)·N/A·NCT00084305·315 enrolled
An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Not yet recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT07441408·2,277 enrolled
Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis
Completed·SSouth Valley University·N/A·NCT04551781·450 enrolled
Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough
Completed·RRoyal Brompton & Harefield NHS Foundation Trust·Phase 3·NCT04429516·44 enrolled
Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT02510937·16 enrolled
Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2/3·NCT00070590·132 enrolled
SVF for Treating Pulmonary Fibrosis Post COVID-19
Completed·—·Phase 1·NCT06304623·40 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)